ECSP055885A - Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor - Google Patents

Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor

Info

Publication number
ECSP055885A
ECSP055885A EC2005005885A ECSP055885A ECSP055885A EC SP055885 A ECSP055885 A EC SP055885A EC 2005005885 A EC2005005885 A EC 2005005885A EC SP055885 A ECSP055885 A EC SP055885A EC SP055885 A ECSP055885 A EC SP055885A
Authority
EC
Ecuador
Prior art keywords
carbostirile
recaptation
serotonine
inhibitors
derivatives
Prior art date
Application number
EC2005005885A
Other languages
English (en)
Inventor
Tetsuro Kikuchi
Taro Iwamoto
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32716306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055885(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ECSP055885A publication Critical patent/ECSP055885A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica de la presente invención que comprende: (1) un derivado de carbostirilo y (2) un inhibidor de recaptación de serotonina en un portador farmacéuticamente aceptable. El derivado de carbostirilo puede ser aripiprazol o un metabolito del mismo, el cual es un estabilizante del sistema dopamina-serotonina. El inhibidor de recaptación de serotonina puede ser fluoxetina, duloxetina, venlafaxina, milnacipran, citalopram, fluvoxamina, paroxetina, sertralina o escitalopram. La composición farmacéutica de la presente invención es útil para tratar a pacientes con desórdenes del humor, particularmente depresión o desorden depresivo mayor.
EC2005005885A 2002-12-27 2005-06-21 Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor ECSP055885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002379003 2002-12-27
US47048103P 2003-05-14 2003-05-14

Publications (1)

Publication Number Publication Date
ECSP055885A true ECSP055885A (es) 2005-11-22

Family

ID=32716306

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005885A ECSP055885A (es) 2002-12-27 2005-06-21 Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor

Country Status (26)

Country Link
US (5) US9387182B2 (es)
EP (2) EP1575590B1 (es)
JP (1) JP4284524B2 (es)
KR (2) KR100842694B1 (es)
CN (2) CN1989968B (es)
AT (1) ATE376419T1 (es)
AU (1) AU2003295235B2 (es)
BR (1) BR0317771A (es)
CA (1) CA2511619C (es)
CY (1) CY1108060T1 (es)
DE (1) DE60317098T2 (es)
DK (1) DK1575590T3 (es)
EC (1) ECSP055885A (es)
ES (1) ES2295677T3 (es)
IL (1) IL169358A (es)
MX (1) MXPA05006857A (es)
MY (1) MY152919A (es)
NO (1) NO333291B1 (es)
NZ (2) NZ540054A (es)
PE (1) PE20040923A1 (es)
PL (1) PL211975B1 (es)
PT (1) PT1575590E (es)
RU (2) RU2356554C2 (es)
SI (1) SI1575590T1 (es)
WO (1) WO2004060374A1 (es)
ZA (1) ZA200503873B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125939B2 (en) 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
WO2006030446A1 (en) * 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US20150174247A1 (en) 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
CN111455019A (zh) * 2018-05-03 2020-07-28 杭州端丽生物技术有限公司 化合物fty720在制备治疗行为和运动异常检测标记物中的应用
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
EP3970710A4 (en) 2019-05-13 2023-06-14 VASTHERA Co. Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES BY ACTIVATION OF AUTOPHAGY
CN114340606A (zh) 2019-05-15 2022-04-12 瓦西特拉有限公司 包含自噬激活剂作为活性成分的用于预防或治疗心脑血管疾病的组合物
US11080484B1 (en) * 2020-10-08 2021-08-03 Omniscient Neurotechnology Pty Limited Natural language processing of electronic records

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en) 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
ZA948357B (en) 1994-06-16 1996-04-24 Lilly Co Eli Potentiation of drug response
PL327600A1 (en) 1995-12-22 1998-12-21 Lilly Co Eli Method of treating depressions
UA48219C2 (uk) 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
US6159963A (en) 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
WO1999020279A1 (en) 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
US6228875B1 (en) 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
US6500827B2 (en) 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
TR200003262T2 (tr) 1998-05-08 2001-03-21 Pharmacia & Upjohn Company Yeni ilaç bileşimleri
EP1077704A4 (en) 1998-05-21 2002-01-30 Lilly Co Eli COMBINATION THERAPY FOR TREATING DEPRESSION
UA78181C2 (en) 1998-05-22 2007-03-15 Lilly Co Eli Combined therapy for treating refractory depressive states
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
IL139591A0 (en) 1998-05-29 2002-02-10 Lilly Co Eli Combination therapy for treatment of bipolar disorders
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
DE69923081T2 (de) 1998-11-23 2005-12-08 Sepracor Inc., Marlborough Desmethylolanzapine enthaltende zusammensetzungen und verfahren
EP1133299A1 (en) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
AU757870B2 (en) 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide
CA2366838A1 (en) 1999-03-18 2000-09-21 Gina Guadagno A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
WO2000059489A2 (en) 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
EP1353675A2 (en) 2001-01-02 2003-10-22 PHARMACIA &amp; UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
EP1369129A4 (en) 2001-03-14 2005-08-03 Ono Pharmaceutical Co ANTIDEPRESSOR REMEDIES CONTAINING AN EP1 ANTAGONIST AS ACTIVE INGREDIENT
EA006396B1 (ru) 2001-04-19 2005-12-29 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си Конденсированные бициклические аминокислоты
JP2004527553A (ja) 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US6582737B2 (en) 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
CA2475839A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2003101492A2 (en) 2002-05-30 2003-12-11 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
JP2005538108A (ja) 2002-07-29 2005-12-15 ポトマック， ファーマ， エルエルシー α−２アドレナリン作動性レセプターアンタゴニストと非定型抗精神病薬精神安定薬との抗精神病薬組み合わせ治療および組成物
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
WO2004039361A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US9125939B2 (en) 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
MXPA06002778A (es) 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
WO2005051488A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY

Also Published As

Publication number Publication date
ATE376419T1 (de) 2007-11-15
HK1145291A1 (en) 2011-04-15
CN1726039B (zh) 2010-08-18
DE60317098T2 (de) 2008-08-07
HK1082411A1 (zh) 2006-06-09
US9694009B2 (en) 2017-07-04
KR20050085906A (ko) 2005-08-29
CN1726039A (zh) 2006-01-25
PT1575590E (pt) 2007-12-06
KR20070093001A (ko) 2007-09-14
JP2004217650A (ja) 2004-08-05
PL378214A1 (pl) 2006-03-20
HK1101550A1 (en) 2007-10-18
EP1575590A1 (en) 2005-09-21
US20200289501A1 (en) 2020-09-17
JP4284524B2 (ja) 2009-06-24
CA2511619A1 (en) 2004-07-22
NO333291B1 (no) 2013-04-29
EP1723957A2 (en) 2006-11-22
PE20040923A1 (es) 2005-01-22
NO20052359L (no) 2005-07-18
AU2003295235B2 (en) 2008-06-19
NZ556779A (en) 2008-12-24
KR100858852B1 (ko) 2008-09-17
ZA200503873B (en) 2006-08-30
CA2511619C (en) 2011-07-12
DE60317098D1 (de) 2007-12-06
US20170258788A1 (en) 2017-09-14
SI1575590T1 (sl) 2008-04-30
CN1989968B (zh) 2011-05-11
PL211975B1 (pl) 2012-07-31
EP1723957A3 (en) 2013-01-23
WO2004060374A1 (en) 2004-07-22
MY152919A (en) 2014-12-15
US20160310489A1 (en) 2016-10-27
US20190151308A1 (en) 2019-05-23
US20140221388A1 (en) 2014-08-07
KR100842694B1 (ko) 2008-07-01
BR0317771A (pt) 2005-11-22
CY1108060T1 (el) 2014-02-12
RU2005123808A (ru) 2006-02-20
RU2356554C2 (ru) 2009-05-27
NO20052359D0 (no) 2005-05-12
AU2003295235A1 (en) 2004-07-29
US9387182B2 (en) 2016-07-12
RU2389490C2 (ru) 2010-05-20
IL169358A0 (en) 2007-07-04
IL169358A (en) 2013-04-30
ES2295677T3 (es) 2008-04-16
DK1575590T3 (da) 2008-02-11
CN1989968A (zh) 2007-07-04
RU2008131331A (ru) 2010-02-10
EP1575590B1 (en) 2007-10-24
MXPA05006857A (es) 2005-08-18
NZ540054A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
MY152919A (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
CO4900058A1 (es) Terapia de combinacion para el tratamiento de psicosis
AR098599A2 (es) Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo
BR0316535A (pt) Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina
EA200100748A1 (ru) Ингибиторы обратного захвата моноаминов для лечения расстройств цнс
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
HUP9701068A2 (hu) Mirtazapint és egy vagy több szelektív szerotoninújrafelvétel-inhibitort tartalmazó gyógyászati készítmény
TR200401291T4 (tr) Depresyon, obsesif kompülsif bozukluk ve psikozda kullanılmak üzre bir serotonin reuptake inhibitörü ve bir atipik antipsikotik kombinasyonu
CL2023003259A1 (es) Composiciones y métodos para el tratamiento de la depresión.
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
Shelton et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
CO6260011A2 (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
PE20080431A1 (es) Composicion farmaceutica que contiene en asociacion saredutant y un inhibidor selectivo de la recaptacion de serotonina o un inhibidor de la recaptacion de serotonina/norepinefrina
UY28401A1 (es) Metabolito
MXPA06002778A (es) Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
PY0626552A (es) Asociación entre agomelatina y un inhibidor de la recaptura de noradrenalina para la fabricacion de un medicamento destinado al tratamiento de los trastornos depresivos
RU2011109649A (ru) Фармацевтическая композиция для профилактики и лечения депрессивных состояний
MX2022011479A (es) Combinacion de antipsicotico atipico e inhibidor de la recaptacion de serotonina.
NO20061427L (no) Kombinasjonen av en serotonin-reoppttaksinhibitor og amoxapin
AR045612A1 (es) Combinacion de inhibidores de la recaptacion de serotonina e inhibidores de la recaptacion de norepinefrina
BRPI0415280A (pt) métodos para o tratamento de sintomas vasomotores